- Home
- AARD vs NEN Comparison
AARD vs NEN Comparison
Compare AARD & NEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- NEN
- Stock Information
- Founded
- AARD 2017
- NEN 1977
- Country
- AARD United States
- NEN United States
- Employees
- AARD N/A
- NEN N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- NEN Building operators
- Sector
- AARD Health Care
- NEN Real Estate
- Exchange
- AARD Nasdaq
- NEN Nasdaq
- Market Cap
- AARD 271.1M
- NEN 262.4M
- IPO Year
- AARD 2025
- NEN N/A
- Fundamental
- Price
- AARD $11.50
- NEN $72.01
- Analyst Decision
- AARD Strong Buy
- NEN
- Analyst Count
- AARD 5
- NEN 0
- Target Price
- AARD $33.00
- NEN N/A
- AVG Volume (30 Days)
- AARD 37.2K
- NEN 545.0
- Earning Date
- AARD 08-18-2025
- NEN 01-01-0001
- Dividend Yield
- AARD N/A
- NEN 6.67%
- EPS Growth
- AARD N/A
- NEN 34.86
- EPS
- AARD N/A
- NEN 4.59
- Revenue
- AARD N/A
- NEN $83,799,689.00
- Revenue This Year
- AARD N/A
- NEN N/A
- Revenue Next Year
- AARD N/A
- NEN N/A
- P/E Ratio
- AARD N/A
- NEN $15.69
- Revenue Growth
- AARD N/A
- NEN 5.86
- 52 Week Low
- AARD $4.88
- NEN $68.98
- 52 Week High
- AARD $19.58
- NEN $84.00
- Technical
- Relative Strength Index (RSI)
- AARD N/A
- NEN 32.09
- Support Level
- AARD N/A
- NEN $72.26
- Resistance Level
- AARD N/A
- NEN $72.51
- Average True Range (ATR)
- AARD 0.00
- NEN 0.06
- MACD
- AARD 0.00
- NEN -0.04
- Stochastic Oscillator
- AARD 0.00
- NEN 0.00
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.